BCR::ABL1 transcript milestone tracking at 3, 6, and 12 months.
Waiting For Required Inputs
Complete the required fields to generate the oncology interpretation.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Use
BCR::ABL1 transcript milestone tracking at 3, 6, and 12 months.
Section 2
Formula & Logic
Clinical Inputs
Timepoint
Categorical selection
BCR::ABL1 (IS)
%
Interpretive Logic
<=10% at 3 months is optimal.
<=1% at 6 months is optimal; >10% is failure.
<=0.1% at 12 months is optimal; >1% is failure.
Section 3
Pearls/Pitfalls
Result Bands
Optimal
Milestone met
Warning
Close follow-up or adherence review needed
Failure
Consider mutation testing or treatment change
Section 4
Next Steps
Suggested Next Steps
01
Interpret the result in the full disease-specific clinical context.
02
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.
Section 5
Evidence Appraisal
Evidence Base
BCR::ABL1 transcript milestone tracking at 3, 6, and 12 months.
OpiCalc Medical Oncology Module • Haematological Malignancies. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.
Section 6
Literature
Context
ELN CML Milestones is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.
